RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 1 filers reported holding RA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $213,358,000 | +1.3% | 4,444,070 | -1.0% | 0.01% | +25.0% |
| Q4 2019 | $210,637,000 | +89.9% | 4,488,324 | -4.3% | 0.01% | +60.0% |
| Q3 2019 | $110,918,000 | -9.1% | 4,689,992 | +15.5% | 0.01% | 0.0% |
| Q2 2019 | $122,061,000 | +71.8% | 4,059,169 | +27.9% | 0.01% | +66.7% |
| Q1 2019 | $71,067,000 | +47.6% | 3,172,586 | +19.9% | 0.00% | +50.0% |
| Q4 2018 | $48,142,000 | +29.8% | 2,645,261 | +29.0% | 0.00% | 0.0% |
| Q3 2018 | $37,084,000 | +142.4% | 2,049,933 | +33.3% | 0.00% | +100.0% |
| Q2 2018 | $15,297,000 | +150.1% | 1,537,331 | +33.5% | 0.00% | – |
| Q1 2018 | $6,117,000 | -24.5% | 1,151,744 | +20.9% | 0.00% | – |
| Q4 2017 | $8,097,000 | -13.9% | 952,580 | +47.9% | 0.00% | – |
| Q3 2017 | $9,405,000 | -19.2% | 644,128 | +3.7% | 0.00% | -100.0% |
| Q2 2017 | $11,644,000 | +58.5% | 621,329 | +80.1% | 0.00% | – |
| Q1 2017 | $7,346,000 | +2725.4% | 345,041 | +1917.0% | 0.00% | – |
| Q4 2016 | $260,000 | – | 17,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Novo Holdings A/S | 2,031,562 | $17,268,000 | 2.42% |
| NEA Management Company, LLC | 3,493,636 | $29,696,000 | 1.23% |
| VHCP Management II, LLC | 544,612 | $4,629,000 | 1.11% |
| RA Capital Management | 1,351,808 | $11,490,000 | 0.96% |
| Rock Springs Capital Management LP | 600,000 | $5,100,000 | 0.23% |
| Rhenman & Partners Asset Management AB | 108,451 | $922,000 | 0.12% |
| Tekla Capital Management LLC | 356,237 | $3,028,000 | 0.12% |
| ELLINGTON MANAGEMENT GROUP LLC | 34,900 | $297,000 | 0.05% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 79,150 | $673,000 | 0.03% |
| Candriam S.C.A. | 151,000 | $1,284,000 | 0.02% |